+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biomarkers Market by Application (Disease Diagnostics, Drug Discovery, Personalized Medicine), Type (Genomic Biomarkers, Metabolomic Biomarkers, Proteomic Biomarkers), Therapeutic Area, End-users, Biomarker Validation, Technologies - Global Forecast 2025-2030- Product Image
Biomarkers Market by Application (Disease Diagnostics, Drug Discovery, Personalized Medicine), Type (Genomic Biomarkers, Metabolomic Biomarkers, Proteomic Biomarkers), Therapeutic Area, End-users, Biomarker Validation, Technologies - Global Forecast 2025-2030- Product Image
Sale

Biomarkers Market by Application (Disease Diagnostics, Drug Discovery, Personalized Medicine), Type (Genomic Biomarkers, Metabolomic Biomarkers, Proteomic Biomarkers), Therapeutic Area, End-users, Biomarker Validation, Technologies - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • November 2024
  • Region: Global
  • 360iResearch™
  • ID: 5337420
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biomarkers Market grew from USD 52.50 billion in 2023 to USD 59.69 billion in 2024. It is expected to continue growing at a CAGR of 14.19%, reaching USD 132.98 billion by 2030.

Biomarkers are biological measures used to assess health or disease conditions, serving as vital tools in diagnostics, drug development, and therapeutic monitoring. The necessity of biomarkers stems from their ability to provide accurate and quantifiable insights into the biological state of an individual, enabling personalized medicine and helping in early disease detection, which ultimately enhances patient outcomes. Applications of biomarkers span various fields, including oncology, cardiology, neurology, and infectious diseases. Key end-use sectors include pharmaceutical and biotechnology companies, diagnostic laboratories, academic and research institutes, and healthcare facilities.

Market growth is significantly driven by the rising prevalence of chronic diseases, advances in genomics, and increasing government and private funding for biomarker research. Technological advancements such as AI and machine learning in biomarker discovery further fuel innovation. However, the market faces challenges such as high cost and complexity of biomarker development, stringent regulatory requirements, and variability in results which can hinder market expansion. Opportunities lie in expanding applications across rare diseases and the integration of biomarkers with digital health technologies.

Strategic recommendations include investing in robust clinical trials, partnerships with technology firms for advanced data analytics, and exploring untapped markets in emerging economies. Limitations include ethical concerns around genetic data and the risk of biomarker over-reliance potentially leading to unwarranted interventions. Key areas for innovation and research involve the development of multi-biomarker panels, collaboration in genomics research, and sensory technology integration for real-time data acquisition. The biomarker market is dynamic, characterized by rapid technological evolution, increasing collaborations among stakeholders, and a strong emphasis on clinical utility and translational research. Embracing these changes with strategically focused R&D investments can leverage growth and sustain a competitive advantage within the market.

Understanding Market Dynamics in the Biomarkers Market

The Biomarkers Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Top market drivers accelerating advancements and investments in biomarker technologies
    • Primary forces driving the evolution and application of biomarkers in clinical settings
    • Significant trends contributing to the dynamic growth and interest in biomarker innovations
  • Market Restraints
    • Understanding privacy concerns related to biomarker data and their role in limiting market progress
    • Analyzing the effect of reimbursement issues on the accessibility and affordability of biomarkers
    • Assessing the impact of high research and development costs on the biomarkers market growth
  • Market Opportunities
    • Collaborations between pharmaceutical companies and research institutions driving biomarker innovations
    • Healthcare sector demand for early disease detection creating opportunities in biomarker research
    • The rise of liquid biopsy as a non-invasive diagnostic tool expanding biomarker applications
  • Market Challenges
    • A shortage of skilled professionals in the biomarker sector limits research and development progress
    • Ethical concerns and patient privacy issues challenge widespread biomarker utilization in research
    • The lack of insurance reimbursement for biomarker testing procedures inhibits market expansion

Exploring Porter’s Five Forces for the Biomarkers Market

Porter’s Five Forces framework further strengthens the insights of the Biomarkers Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Biomarkers Market

External macro-environmental factors deeply influence the performance of the Biomarkers Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Biomarkers Market

The Biomarkers Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Biomarkers Market

The Biomarkers Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Biomarkers Market

The Biomarkers Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abcam PLC, APIS Assay Technologies Limited, Augurex Life Sciences Corp, Bio-Rad Laboratories, Inc., BioAgilytix, Biocrates Life Sciences AG, Biofourmis Inc., Biognosys AG, BioStarks, Charles River Laboratories, Inc., Elo Health, Inc., F. Hoffmann-La Roche, Ltd., Merck KgaA, Nightingale Health Plc, Owkin Inc., Owlstone Medical Limited, PerkinElmer, Inc., Personalis, Inc., Proteomedix AG, QIAGEN GmbH, Siemens Healthineers AG, Sino Biological Inc., Thermo Fisher Scientific, Inc., and VivoSense, Inc.

Market Segmentation & Coverage

This research report categorizes the Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Application
    • Disease Diagnostics
      • Cardiovascular Diseases
      • Infectious Diseases
        • Bacterial Infections
        • Viral Infections
      • Oncology
    • Drug Discovery
      • Lead Optimization
      • Target Identification
    • Personalized Medicine
      • Companion Diagnostics
      • Therapeutic Segment
  • Type
    • Genomic Biomarkers
      • DNA-based Biomarkers
      • RNA-based Biomarkers
    • Metabolomic Biomarkers
    • Proteomic Biomarkers
      • Protein Expression
  • Therapeutic Area
    • Cardiology
      • Heart Failure
      • Myocardial Infarction
    • Neurology
      • Alzheimer's Disease
      • Parkinson's Disease
    • Oncology
      • Breast Cancer Biomarkers
      • Lung Cancer Biomarkers
  • End Users
    • Clinical Laboratories
      • Hospital-Based Labs
      • Independent Labs
    • Pharmaceutical Companies
      • Biopharmaceutical Companies
      • Generic Pharmaceutical Companies
    • Research Organizations
  • Biomarker Validation
    • Analytical Validation
      • Assay Development
      • Reference Standard
    • Clinical Validation
      • Sensitivity and Specificity Studies
    • Regulatory Validation
      • Regulatory Approval Pathways
  • Technologies
    • Imaging Technologies
      • MRI
      • PET Scans
    • Mass Spectrometry
    • Next-generation Sequencing
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States (California, Florida, Illinois, New York, Ohio, Pennsylvania, Texas)
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  • Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  • Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  • Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  • Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  • Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  • What is the current size of the market, and how is it expected to grow?
  • Which products, segments, and regions present the most attractive investment opportunities?
  • What are the prevailing technology trends and regulatory factors influencing the market?
  • How do top vendors rank regarding market share and competitive positioning?
  • What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Top market drivers accelerating advancements and investments in biomarker technologies
5.1.1.2. Primary forces driving the evolution and application of biomarkers in clinical settings
5.1.1.3. Significant trends contributing to the dynamic growth and interest in biomarker innovations
5.1.2. Restraints
5.1.2.1. Understanding privacy concerns related to biomarker data and their role in limiting market progress
5.1.2.2. Analyzing the effect of reimbursement issues on the accessibility and affordability of biomarkers
5.1.2.3. Assessing the impact of high research and development costs on the biomarkers market growth
5.1.3. Opportunities
5.1.3.1. Collaborations between pharmaceutical companies and research institutions driving biomarker innovations
5.1.3.2. Healthcare sector demand for early disease detection creating opportunities in biomarker research
5.1.3.3. The rise of liquid biopsy as a non-invasive diagnostic tool expanding biomarker applications
5.1.4. Challenges
5.1.4.1. A shortage of skilled professionals in the biomarker sector limits research and development progress
5.1.4.2. Ethical concerns and patient privacy issues challenge widespread biomarker utilization in research
5.1.4.3. The lack of insurance reimbursement for biomarker testing procedures inhibits market expansion
5.2. Market Segmentation Analysis
5.2.1. Product & Service: Growing adoption of sophisticated and user-friendly biomarker software to handle the complexity of biological data
5.2.2. Application: Growing applications of biomarkers in drug development to determine the efficacy and safety of the product
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Biomarkers Market, by Application
6.1. Introduction
6.2. Disease Diagnostics
6.2.1. Cardiovascular Diseases
6.2.2. Infectious Diseases
6.2.2.1. Bacterial Infections
6.2.2.2. Viral Infections
6.2.3. Oncology
6.3. Drug Discovery
6.3.1. Lead Optimization
6.3.2. Target Identification
6.4. Personalized Medicine
6.4.1. Companion Diagnostics
6.4.2. Therapeutic Segment
7. Biomarkers Market, by Type
7.1. Introduction
7.2. Genomic Biomarkers
7.2.1. DNA-based Biomarkers
7.2.2. RNA-based Biomarkers
7.3. Metabolomic Biomarkers
7.4. Proteomic Biomarkers
7.4.1. Protein Expression
8. Biomarkers Market, by Therapeutic Area
8.1. Introduction
8.2. Cardiology
8.2.1. Heart Failure
8.2.2. Myocardial Infarction
8.3. Neurology
8.3.1. Alzheimer's Disease
8.3.2. Parkinson's Disease
8.4. Oncology
8.4.1. Breast Cancer Biomarkers
8.4.2. Lung Cancer Biomarkers
9. Biomarkers Market, by End Users
9.1. Introduction
9.2. Clinical Laboratories
9.2.1. Hospital-Based Labs
9.2.2. Independent Labs
9.3. Pharmaceutical Companies
9.3.1. Biopharmaceutical Companies
9.3.2. Generic Pharmaceutical Companies
9.4. Research Organizations
10. Biomarkers Market, by Biomarker Validation
10.1. Introduction
10.2. Analytical Validation
10.2.1. Assay Development
10.2.2. Reference Standard
10.3. Clinical Validation
10.3.1. Sensitivity and Specificity Studies
10.4. Regulatory Validation
10.4.1. Regulatory Approval Pathways
11. Biomarkers Market, by Technologies
11.1. Introduction
11.2. Imaging Technologies
11.2.1. MRI
11.2.2. PET Scans
11.3. Mass Spectrometry
11.4. Next-generation Sequencing
12. Americas Biomarkers Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Biomarkers Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Biomarkers Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
15.3.1. Owlstone Medical's Novel Initiatives Receive the Bill & Melinda Gates Foundation Funding
15.3.2. Pioneering Research Collaboration to Enhance Treatment for Metastatic Colorectal Cancer
15.3.3. FDA Initiates Pilot Program to Regulate Companion Diagnostic Tests for Oncology Drugs
15.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. BIOMARKERS MARKET MULTI-CURRENCY
FIGURE 2. BIOMARKERS MARKET MULTI-LANGUAGE
FIGURE 3. BIOMARKERS MARKET RESEARCH PROCESS
FIGURE 4. BIOMARKERS MARKET SIZE, 2023 VS 2030
FIGURE 5. GLOBAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
FIGURE 13. GLOBAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL BIOMARKERS MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
FIGURE 15. GLOBAL BIOMARKERS MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2023 VS 2030 (%)
FIGURE 17. GLOBAL BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2023 VS 2030 (%)
FIGURE 19. GLOBAL BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. AMERICAS BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. AMERICAS BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. UNITED STATES BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 23. UNITED STATES BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 29. BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. BIOMARKERS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BIOMARKERS MARKET DYNAMICS
TABLE 7. GLOBAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOMARKERS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOMARKERS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOMARKERS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOMARKERS MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOMARKERS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOMARKERS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC SEGMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOMARKERS MARKET SIZE, BY DNA-BASED BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOMARKERS MARKET SIZE, BY RNA-BASED BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOMARKERS MARKET SIZE, BY METABOLOMIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOMARKERS MARKET SIZE, BY PROTEIN EXPRESSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOMARKERS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOMARKERS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOMARKERS MARKET SIZE, BY BREAST CANCER BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOMARKERS MARKET SIZE, BY LUNG CANCER BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOMARKERS MARKET SIZE, BY HOSPITAL-BASED LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOMARKERS MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIOMARKERS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIOMARKERS MARKET SIZE, BY GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIOMARKERS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BIOMARKERS MARKET SIZE, BY ASSAY DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BIOMARKERS MARKET SIZE, BY REFERENCE STANDARD, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BIOMARKERS MARKET SIZE, BY SENSITIVITY AND SPECIFICITY STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BIOMARKERS MARKET SIZE, BY REGULATORY APPROVAL PATHWAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BIOMARKERS MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BIOMARKERS MARKET SIZE, BY PET SCANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 138. CANADA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. CANADA BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 140. CANADA BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 141. CANADA BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 142. CANADA BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 143. CANADA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 144. CANADA BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 145. CANADA BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 146. CANADA BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 147. CANADA BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 148. CANADA BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 149. CANADA BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 150. CANADA BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 151. CANADA BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 152. CANADA BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 153. CANADA BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 154. CANADA BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 155. CANADA BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 156. CANADA BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 157. CANADA BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 158. CANADA BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 159. MEXICO BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. MEXICO BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 161. MEXICO BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 162. MEXICO BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 163. MEXICO BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 164. MEXICO BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 165. MEXICO BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 166. MEXICO BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 167. MEXICO BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 168. MEXICO BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 169. MEXICO BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 170. MEXICO BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 171. MEXICO BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 172. MEXICO BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 173. MEXICO BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 174. MEXICO BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 175. MEXICO BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 176. MEXICO BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 177. MEXICO BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 178. MEXICO BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 179. MEXICO BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 183. UNITED STATES BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 184. UNITED STATES BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 185. UNITED STATES BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 186. UNITED STATES BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 187. UNITED STATES BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 188. UNITED STATES BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 189. UNITED STATES BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 190. UNITED STATES BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 191. UNITED STATES BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 192. UNITED STATES BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 193. UNITED STATES BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 194. UNITED STATES BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 195. UNITED STATES BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 196. UNITED STATES BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 197. UNITED STATES BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 198. UNITED STATES BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 199. UNITED STATES BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 200. UNITED STATES BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 201. UNITED STATES BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 211. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 212. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 213. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 214. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 215. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 216. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 218. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 219. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 220. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 221. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 222. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 223. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 224. AUSTRALIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. AUSTRALIA BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 226. AUSTRALIA BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 227. AUSTRALIA BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 228. AUSTRALIA BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 230. AUSTRALIA BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 231. AUSTRALIA BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 232. AUSTRALIA BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 233. AUSTRALIA BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 234. AUSTRALIA BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 235. AUSTRALIA BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 236. AUSTRALIA BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 237. AUSTRALIA BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 238. AUSTRALIA BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 239. AUSTRALIA BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 240. AUSTRALIA BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 241. AUSTRALIA BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 242. AUSTRALIA BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 243. AUSTRALIA BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 244. AUSTRALIA BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 245. CHINA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 246. CHINA BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 247. CHINA BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 248. CHINA BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 249. CHINA BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 250. CHINA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 251. CHINA BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 252. CHINA BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 253. CHINA BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 254. CHINA BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 255. CHINA BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 256. CHINA BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 257. CHINA BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 258. CHINA BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 259. CHINA BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 260. CHINA BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 261. CHINA BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 262. CHINA BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 263. CHINA BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 264. CHINA BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 265. CHINA BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 266. INDIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 267. INDIA BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 268. INDIA BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 269. INDIA BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 270. INDIA BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 271. INDIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 272. INDIA BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 273. INDIA BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 274. INDIA BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 275. INDIA BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 276. INDIA BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 277. INDIA BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 278. INDIA BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 279. INDIA BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 280. INDIA BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 281. INDIA BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 282. INDIA BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 283. INDIA BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 284. INDIA BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 285. INDIA BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 286. INDIA BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 287. INDONESIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 288. INDONESIA BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 289. INDONESIA BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 290. INDONESIA BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 291. INDONESIA BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 292. INDONESIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 293. INDONESIA BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 294. INDONESIA BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 295. INDONESIA BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 296. INDONESIA BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 297. INDONESIA BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 298. INDONESIA BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 299. INDONESIA BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 300. INDONESIA BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 301. INDONESIA BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 302. INDONESIA BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 303. INDONESIA BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 304. INDONESIA BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 305. INDONESIA BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 306. INDONESIA BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 307. INDONESIA BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 308. JAPAN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 309. JAPAN BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 310. JAPAN BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 311. JAPAN BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 312. JAPAN BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 313. JAPAN BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 314. JAPAN BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 315. JAPAN BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 316. JAPAN BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 317. JAPAN BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 318. JAPAN BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 319. JAPAN BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 320. JAPAN BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 321. JAPAN BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 322. JAPAN BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 323. JAPAN BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 324. JAPAN BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 325. JAPAN BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 326. JAPAN BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 327. JAPAN BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 328. JAPAN BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 329. MALAYSIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 330. MALAYSIA BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 331. MALAYSIA BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 332. MALAYSIA BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 333. MALAYSIA BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 334. MALAYSIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 335. MALAYSIA BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 336. MALAYSIA BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 337. MALAYSIA BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 338. MALAYSIA BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 339. MALAYSIA BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 340. MALAYSIA BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 341. MALAYSIA BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 342. MALAYSIA BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 343. MALAYSIA BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 344. MALAYSIA BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 345. MALAYSIA BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 346. MALAYSIA BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 347. MALAYSIA BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 348. MALAYSIA BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 349. MALAYSIA BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 350. PHILIPPINES BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 351. PHILIPPINES BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 352. PHILIPPINES BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 353. PHILIPPINES BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 354. PHILIPPINES BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 355. PHILIPPINES BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 356. PHILIPPINES BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 357. PHILIPPINES BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 358. PHILIPPINES BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 359. PHILIPPINES BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 360. PHILIPPINES BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 361. PHILIPPINES BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 362. PHILIPPINES BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 363. PHILIPPINES BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 364. PHILIPPINES BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 365. PHILIPPINES BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 366. PHILIPPINES BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD M

Companies Mentioned

  • Abbott Laboratories
  • Abcam PLC
  • APIS Assay Technologies Limited
  • Augurex Life Sciences Corp
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix
  • Biocrates Life Sciences AG
  • Biofourmis Inc.
  • Biognosys AG
  • BioStarks
  • Charles River Laboratories, Inc.
  • Elo Health, Inc.
  • F. Hoffmann-La Roche, Ltd.
  • Merck KgaA
  • Nightingale Health Plc
  • Owkin Inc.
  • Owlstone Medical Limited
  • PerkinElmer, Inc.
  • Personalis, Inc.
  • Proteomedix AG
  • QIAGEN GmbH
  • Siemens Healthineers AG
  • Sino Biological Inc.
  • Thermo Fisher Scientific, Inc.
  • VivoSense, Inc

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages186
PublishedNovember 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 59.69 billion
Forecasted Market Value ( USD ) by 2030 $ 132.98 billion
Compound Annual Growth Rate14.1%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Genomic Biomarker Market by Product, Type, Disease Indication, End-User - Global Forecast 2025-2030 - Product Image

Genomic Biomarker Market by Product, Type, Disease Indication, End-User - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Genomics Biomarkers Market by Type, by Disease Indication, by Validation, by End- User, and by Region - Product Image

Genomics Biomarkers Market by Type, by Disease Indication, by Validation, by End- User, and by Region

  • Report
  • 200 Pages
  • Global
From
Genomic Biomarker Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Genomic Biomarker Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 104 Pages
  • Global
From
Metabolomics Biomarker Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology - Product Image

Metabolomics Biomarker Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology

  • Report
  • 93 Pages
  • Global
From
2024 Global Forecast for Genomic Biomarkers Market (2025-2030 Outlook)-High Tech & Emerging Markets Report - Product Image

2024 Global Forecast for Genomic Biomarkers Market (2025-2030 Outlook)-High Tech & Emerging Markets Report

  • Report
  • 132 Pages
  • Global
From

About the Metabolomics Biomarker Market

Metabolomics biomarkers are a type of biomarker used to measure and analyze the metabolites present in a biological sample. Metabolites are small molecules that are produced as a result of metabolic processes, and they can provide valuable information about the health of an individual. Metabolomics biomarkers are used to identify and quantify metabolites in order to gain insight into the metabolic pathways of an organism. This information can be used to diagnose diseases, monitor the progression of a disease, and evaluate the effectiveness of treatments. Metabolomics biomarkers are used in a variety of fields, including drug discovery, toxicology, nutrition, and personalized medicine. They are also used to identify biomarkers for diseases such as cancer, diabetes, and cardiovascular disease. Companies in the metabolomics biomarker market include Metabolon, Biocrates Life Sciences, Metabolomic Technologies, Metabolon, and Metabolomics Technologies. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.